Tag: Allergan

Allergan is a multi-national pharmaceutical that produces branded and generic drugs, and performs pharmaceutical research and development. Formerly known as Actavis.

Allergan Marks Opening of New €160m Biologics Facility in Westport

Allergan plc, the global integrated biopharmaceutical leader headquartered in Ireland, marked the opening of its €160m state-of-the-art Biologics 2 facility at its Westport Campus in Co. Mayo, Ireland...

Nestlé is Purchasing Allergan Pancreatic Replacement Enzymes

Nestlé announced that it has entered into an asset purchase agreement with Allergan to acquire the gastrointestinal medication Zenpep. This move aims to expand the company's medical nutrition business...

AbbVie and Allergan Receive Conditional Approval from the European Commission

The European Commission approved AbbVie's merger with Allergan on the condition the companies sell off Allergan's late-stage IL-23 inhibitor brazikumab. That stipulation is far from a deal-breaker; Al...

Amgen and Allergan Filed for FDA Approval of Biosimilar Version of Roche’s Rituxan

molecule
Amgen and Allergan have filed for approval of their biosimilar version of Roche’s CD20-targeting drug Rituxan with the FDA, vying to become the third copycat version of the blockbuster drug approved i...

Allergan Celebrates 30th Anniversary of BOTOX®

allergan
Allergan plc is commemorating the beginning of the 30th anniversary celebration for BOTOX® this year with the ringing of the New York Stock Exchange opening bell. Over the past 30 years, more than ...

Allergan’s Ubrogepant under Registration for Treatment of Acute Migraines

allergan
Irish pharmaceutical company Allergan’s ubrogepant is currently in pre-registration for the treatment of acute migraines. It’s an oral pill belonging to a novel class of medications known as calcitoni...

Allergan and Exicure Entered into Global Collaboration Agreement

Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals ...

FDA Granted Qualified Infectious Disease Product and Fast Track Designation for ATM-AVI

allergan
Allergan plc announced the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation and Fast Track Designation for ATM-AVI (aztreonam and avibactam),...

Allergan Agreed to Pay $750m to Settle Alzheimer’s Lawsuits

Allergan has agreed to pay $750 million to settle lawsuits in the US brought by direct purchasers of its Namenda Alzheimer’s drug in the US. The settlement means that Dublin, Ireland headquartered ...

FDA Approved Allergan sBLA for BOTOX

Allergan plc announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) for BOTOX® for the treatment of pediatric patients (2 t...

Allergan Shareholders Approved Proposed Acquisition of Allergan by AbbVie

Allergan plc announced that its shareholders have voted to approve the previously announced proposed acquisition of Allergan by AbbVie Inc. As described below, more than 99 percent of the votes cas...

Allergan Presented Positive Data from Clinical Studies of Investigational Abicipar

allergan
Allergan plc., a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners, a clinical-stage biopharmaceutical company developing a new class of d...

Allergan Expands REFRESH® Portfolio

Allergan plc, a leading global pharmaceutical company with a more than 70-year heritage in eye care, announced the launch of three new over-the-counter (OTC)  REFRESH® RELIEVA™ products: REFRESH® RELI...

FDA Approved Use of Allergan’s Juvéderm VOLUMA®

Allergan plc announced it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA® XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE™ cannula for cheek au...

Allergan Reached Settlement with Plaintiffs in Federal Opioid Litigation

allergan
Allergan plc announced that the Company and its U.S. subsidiaries have reached a settlement with plaintiffs scheduled for trial in October 2019 in the federal opioid multidistrict litigation. As part ...

Amgen and Allergan Announced Positive Results from Clinical Study of Rituxan®

research
Amgen and Allergan plc. announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan® (rituximab), compared to...